myirislogo
24 October, 2019 01:57 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
Infosys 650.75 1.16
Tata Motors 132.65 0.57
Tata Power 60.80 2.62
Adani Ports 396.25 5.85
State Bank O 275.50 1.87
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Wockhardt Limited
Wockhardt Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:532300NSE:WOCKPHARMABloomberg:WPL@INReuters:WCKH.BO
Market Lot: 1Face Value: 5ISIN Demat: INE049B01025
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
21-JAN-19 Pharmaceutical and biotechnology major Wockhardt has received approval from the United States Food & Drug Administration (US FDA) for an ANDA for lOOmg and 400mg tablets 07-AUG-17 Wockhardt has received approval from the United States Food & Drug Administration (USFDA) for an ANDA for 1gm, and 2gm injections of Oxacillin. The pharma major is expected to launch this product in the United States, soon. The product is being manufactured...   More..
Business Profile Future Plans
CEO Talk
Wockhardt Ltd is exploring possibilities of co-licensing WCK-771 and WCK-919. The company intends to focus essentially on the anti-infective therapeutic segment as it accounts for 12 per cent of the total pharma market and is the third largest therapeutic segment.   Habil Khorakiwala
One To One
Recent news
Latest News
Wockhardt receives USFDA nod for antibiotic Oxacillin injection  -IRIS 07-Aug-17
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Dec-2017(9)31-Mar-2017 (12)31-Mar-2016(12)
Net sales 15639.5022975.2017135.70
Other Income462.902483.10317.20
Total Income16102.4025458.3017452.90
Cost of goods sold17239.2024270.5015882.30
OPBDIT-1136.801187.801570.60
PAT-1037.801371.20260.70
Gross Block---
Equity capital-0.00-
EPS (Rs.)-0.00-
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-NA-
Debt / Equity (x)---
Operating margin (% of OI)-7.1 4.7 9.0
Net margin (% of OI)-6.4 5.4 1.5
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Wockhardt Towers
Bandra Kurla Complex
Bandra (East)
Mumbai
Maharashtra-400 051
PHONE
(022) 2653 4444
FAX
(022) 2653 4242
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer